AnaptysBio (NASDAQ:ANAB) Stock Price Up 8.2%

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price rose 8.2% on Friday . The stock traded as high as $20.52 and last traded at $20.42. Approximately 253,023 shares were traded during trading, a decline of 19% from the average daily volume of 312,846 shares. The stock had previously closed at $18.87.

Analyst Ratings Changes

A number of brokerages have issued reports on ANAB. Stifel Nicolaus began coverage on AnaptysBio in a research report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, April 1st. Piper Sandler began coverage on shares of AnaptysBio in a research note on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective for the company. Leerink Partnrs reiterated an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. Finally, Wells Fargo & Company began coverage on shares of AnaptysBio in a research note on Thursday, April 11th. They set an “overweight” rating and a $56.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.22.

AnaptysBio Stock Performance

The stock has a market cap of $561.96 million, a price-to-earnings ratio of -3.41 and a beta of -0.30. The business’s fifty day simple moving average is $22.99 and its 200 day simple moving average is $20.57.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The business had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. As a group, analysts forecast that AnaptysBio, Inc. will post -6.17 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other news, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other AnaptysBio news, CEO Daniel Faga sold 145,940 shares of the firm’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the sale, the chief executive officer now owns 752,087 shares in the company, valued at approximately $17,132,541.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric J. Loumeau sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now owns 3,240 shares of the company’s stock, valued at approximately $81,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 157,005 shares of company stock worth $3,586,199. 35.50% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

A number of institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio during the first quarter worth $38,000. China Universal Asset Management Co. Ltd. lifted its position in AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 2,390 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock worth $106,000 after acquiring an additional 3,381 shares during the last quarter. Quest Partners LLC bought a new position in AnaptysBio in the 4th quarter valued at approximately $119,000. Finally, SG Americas Securities LLC acquired a new stake in AnaptysBio during the 4th quarter valued at approximately $126,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.